Endogenous endophthalmitis in a rheumatoid patient on tumor necrosis factor alpha blocker

Area of Science:

• Rheumatology
• Ophthalmology
• Immunology

Background:

• Anti-tumor necrosis factor (TNF) therapies represent a significant advancement in treating rheumatic diseases.
• The comprehensive evaluation of all potential adverse events within clinical trials prior to treatment approval remains a concern.

Observation:

• This report details a case of endogenous endophthalmitis, an unusual and severe complication.
• The patient was diagnosed with rheumatoid arthritis and was undergoing treatment with a TNF alpha blocker.

Findings:

• The case highlights a rare but severe complication associated with TNF blocker therapy.
• Endogenous endophthalmitis occurred in a rheumatoid arthritis patient receiving anti-TNF treatment.

Implications:

• Clinicians prescribing TNF blockers must be vigilant for uncommon and severe adverse events.
• Awareness of potential complications like endophthalmitis is crucial for patient safety in rheumatic disease management.